Triptorelin: 4 agencies, 2005–2021
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 16.2 years separate the first record, 9 May 2005 at SMC (Scotland), from the most recent, 2021 at PBAC (Australia).
HAS (France) changed its position: recommended on 15 Oct 2014, not recommended by 19 Sep 2018.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for triptorelin, 1 submission was never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2021; on this evidence the file is dormant.
The programme is broad: 8 distinct indication wordings are recorded for triptorelin by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 17 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess triptorelin, on 9 May 2005; PBAC (Australia) did not open a file until 2016 — an unusually long tail of 11.2 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 13 years in total.
4 of the 4 agencies here assessed triptorelin more than once, HAS (France) most often at 8 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed triptorelin.
The full ledger for triptorelin reads 9 recommended, 4 other, 2 not recommended and 1 non-submission, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2021 | Central precocious puberty (CPP) | Recommended | source |
| SMC (Scotland) | 7 Oct 2019 | Triptorelin (Decapeptyl SR 3 mg), a gonadotropin-releasing-hormone (GnRH) agonist, is indicated as adjuvant treatment, in combination with tamoxifen or an aromatase inhib… | accepted | source |
| HAS (France) | 19 Sep 2018 | Indication extension | SMR insufficient | source |
| SMC (Scotland) | 11 Jun 2012 | Reversible reduction of testosterone to castrate levels in order to decrease sexual drive in adult men with severe sexual deviations. | not recommended | source |
| AWMSG (Wales) | 6 Jun 2011 | Treatment of patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration. T… | outside AWMSG criteria | source |
12 further decisions for triptorelin, across 4 agencies, are not shown here. They link to 8 further source documents.
Related molecules
- leuprorelin — same ATC class L02A — Endocrine therapy
- glibenclamide — also decided by SMC in 2019Q4
- axicabtagene ciloleucel — also decided by SMC in 2019Q4
- ibrutinib — also decided by SMC in 2019Q4
- lusutrombopag — also decided by SMC in 2019Q4
- risankizumab — also decided by SMC in 2019Q4
Coverage: 17 decisions for triptorelin from 4 agencies, 2005 to 2021. Data to 7 Sep 2026. ATC class L02A — Endocrine therapy. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.